Hirudin inhibits cell growth via ERK/MAPK signaling in human glioma

被引:0
|
作者
Zhao, Li [1 ]
机构
[1] First Peoples Hosp Yuhang, Dept Gastroenterol, Hangzhou 310016, Zhejiang, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2015年 / 8卷 / 11期
关键词
Hirudin; ERK/MAPK signaling; glioma; cell growth; MALIGNANT GLIOMAS; RECOMBINANT; GLIOBLASTOMA; METAANALYSIS; MANAGEMENT; PEPTIDE; PATHWAY; DRUG;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Glioma is one of the most common intracranial tumors, and the prognosis is poor though more and more treatments are employed. ERK/MAPK signaling has been reported to be associated with glioma. In the present study, we aimed to investigate hirudin as an antineoplastic drug inhibits ERK/MAPK signaling in glioma growth in vitro. The cell proliferation and apoptosis rate were detected using MTS and Annexin V staining assay, cell cycle distribution was detected using flowcytometry assay. Furthermore, the relevant molecules of ERK/MAPK signaling were examined using Western blot analysis and immunofluorescence staining assay. We provide the first evidence that hirudin increase inactivation state of ERK1/2, down-regulate the expression of canonical ERK/MAPK signaling pathway and establish an important role for hirudin in the treatment of glioma cells.
引用
收藏
页码:20983 / 20987
页数:5
相关论文
共 50 条
  • [1] Astragaloside IV inhibits progression of glioma via blocking MAPK/ERK signaling pathway
    Li, Bin
    Wang, Fei
    Liu, Ningtao
    Shen, Wen
    Huang, Tao
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 491 (01) : 98 - 103
  • [2] Knockdown of RNF6 inhibits HeLa cervical cancer cell growth via suppression of MAPK/ERK signaling
    Zhu, Kang
    Bai, He
    Mu, Mingzhu
    Xue, Yuanyuan
    Duan, Zhao
    FEBS OPEN BIO, 2021, 11 (07): : 2041 - 2049
  • [3] Hirudin inhibits glioma growth through mTOR-regulated autophagy
    Ma, Ying
    Wu, Senbin
    Zhao, Fanyi
    Li, Huifeng
    Li, Qiaohong
    Zhang, Jingzhi
    Li, Hua
    Yuan, Zhongmin
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (18) : 2701 - 2713
  • [4] Berberine inhibits cell growth via Wnt/beta-catenin signaling in glioma
    Xie, Dajiang
    Li, Xinwei
    Qi, Xuchen
    Wan, Yingfeng
    Zhu, Yinxin
    Yang, Shuxu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (01): : 652 - 657
  • [5] Knockdown of PEBP4 inhibits human glioma cell growth and invasive potential via ERK1/2 signaling pathway
    Huang, Ren-qiang
    Wang, Song-qing
    Zhu, Qing-bao
    Guo, Shan-cheng
    Shi, Dong-liang
    Chen, Feng
    Fang, Yuan-cheng
    Chen, Rui
    Lu, Yi-cheng
    MOLECULAR CARCINOGENESIS, 2019, 58 (01) : 135 - 143
  • [6] Knockdown of Angiopoietin-Like Protein 2 Inhibits Proliferation and Invasion in Glioma Cells via Suppressing the ERK/MAPK Signaling Pathway
    Yang, Li-Kun
    Zhu, Jie
    Chen, Yu-Hua
    Wang, Dong-Liang
    Li, Hua
    Zhang, Liang-Jun
    Zhou, Jing-Ru
    Liu, Wei
    ONCOLOGY RESEARCH, 2017, 25 (08) : 1349 - 1355
  • [7] Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways
    Wang, Guangxiu
    Dai, Fang
    Yu, Kai
    Jia, Zhifan
    Zhang, Anling
    Huang, Qiang
    Kang, Chunsheng
    Jiang, Hao
    Pu, Peiyu
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (04) : 1739 - 1747
  • [8] Resveratrol inhibits glioma cell growth via targeting LRIG1
    Liu, Lianfang
    Zhang, Yonghua
    Zhu, Kai
    Song, Lili
    Tao, Minxian
    Huang, Pan
    Pan, Yingying
    JOURNAL OF BUON, 2018, 23 (02): : 403 - 409
  • [9] Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling
    Lu, Liang
    Li, Cuixian
    Li, Dong
    Wang, Ying
    Zhou, Chun
    Shao, Weiwei
    Peng, Jin
    You, Yan
    Zhang, Xinwen
    Shen, Xiaoyan
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2013, 381 (1-2) : 273 - 282
  • [10] Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells
    Wang, Yingge
    Gao, Shan
    Wang, Weiguang
    Liang, Jingyan
    MOLECULAR MEDICINE REPORTS, 2016, 14 (06) : 5732 - 5738